Abstract
Summary
Liposomes are spherical nano-sized bilayered vesicles or “bags” in which an aqueous volume is entirely closed within a membrane composed of lipid (fat) molecules, usually phospholipids. The components within the bilayer define the rigidity/ fluidity and charge of the bilayer.
The global Liposomes market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Liposomes Industry Forecast” looks at past sales and reviews total world Liposomes sales in 2023, providing a comprehensive analysis by region and market sector of projected Liposomes sales for 2024 through 2030. With Liposomes sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liposomes industry.
This Insight Report provides a comprehensive analysis of the global Liposomes landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liposomes portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Liposomes market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposomes and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposomes.
North America dominated the market with market share of 44.2% due to the high medical level. Following North America, Europe is the second largest market with market share of 36%. Asian Pacific regions are the third largest market with developed countries like Japan and many developing countries like China. Its market share is about 12.85%.
This report presents a comprehensive overview, market shares, and growth opportunities of Liposomes market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Segmentation by application
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
Spectrum Pharmaceuticals
Shanghai New Asia
Key Questions Addressed in this Report
What is the 10-year outlook for the global Liposomes market?
What factors are driving Liposomes market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liposomes market opportunities vary by end market size?
How does Liposomes break out type, application?
The global Liposomes market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Liposomes Industry Forecast” looks at past sales and reviews total world Liposomes sales in 2023, providing a comprehensive analysis by region and market sector of projected Liposomes sales for 2024 through 2030. With Liposomes sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liposomes industry.
This Insight Report provides a comprehensive analysis of the global Liposomes landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liposomes portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Liposomes market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposomes and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposomes.
North America dominated the market with market share of 44.2% due to the high medical level. Following North America, Europe is the second largest market with market share of 36%. Asian Pacific regions are the third largest market with developed countries like Japan and many developing countries like China. Its market share is about 12.85%.
This report presents a comprehensive overview, market shares, and growth opportunities of Liposomes market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Segmentation by application
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
Spectrum Pharmaceuticals
Shanghai New Asia
Key Questions Addressed in this Report
What is the 10-year outlook for the global Liposomes market?
What factors are driving Liposomes market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liposomes market opportunities vary by end market size?
How does Liposomes break out type, application?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Liposomes Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Liposomes by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Liposomes by Country/Region, 2019, 2023 & 2030
2.2 Liposomes Segment by Type
2.2.1 Liposomal Doxorubicin
2.2.2 Liposomal Amphoteracin B
2.2.3 Liposomal Paclitaxel
2.2.4 Others
2.3 Liposomes Sales by Type
2.3.1 Global Liposomes Sales Market Share by Type (2019-2024)
2.3.2 Global Liposomes Revenue and Market Share by Type (2019-2024)
2.3.3 Global Liposomes Sale Price by Type (2019-2024)
2.4 Liposomes Segment by Application
2.4.1 Fungal Infection Therapy
2.4.2 Cancer & Tumor Therapy
2.4.3 Others
2.5 Liposomes Sales by Application
2.5.1 Global Liposomes Sale Market Share by Application (2019-2024)
2.5.2 Global Liposomes Revenue and Market Share by Application (2019-2024)
2.5.3 Global Liposomes Sale Price by Application (2019-2024)
3 Global Liposomes by Company
3.1 Global Liposomes Breakdown Data by Company
3.1.1 Global Liposomes Annual Sales by Company (2019-2024)
3.1.2 Global Liposomes Sales Market Share by Company (2019-2024)
3.2 Global Liposomes Annual Revenue by Company (2019-2024)
3.2.1 Global Liposomes Revenue by Company (2019-2024)
3.2.2 Global Liposomes Revenue Market Share by Company (2019-2024)
3.3 Global Liposomes Sale Price by Company
3.4 Key Manufacturers Liposomes Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Liposomes Product Location Distribution
3.4.2 Players Liposomes Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Liposomes by Geographic Region
4.1 World Historic Liposomes Market Size by Geographic Region (2019-2024)
4.1.1 Global Liposomes Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Liposomes Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Liposomes Market Size by Country/Region (2019-2024)
4.2.1 Global Liposomes Annual Sales by Country/Region (2019-2024)
4.2.2 Global Liposomes Annual Revenue by Country/Region (2019-2024)
4.3 Americas Liposomes Sales Growth
4.4 APAC Liposomes Sales Growth
4.5 Europe Liposomes Sales Growth
4.6 Middle East & Africa Liposomes Sales Growth
5 Americas
5.1 Americas Liposomes Sales by Country
5.1.1 Americas Liposomes Sales by Country (2019-2024)
5.1.2 Americas Liposomes Revenue by Country (2019-2024)
5.2 Americas Liposomes Sales by Type
5.3 Americas Liposomes Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Liposomes Sales by Region
6.1.1 APAC Liposomes Sales by Region (2019-2024)
6.1.2 APAC Liposomes Revenue by Region (2019-2024)
6.2 APAC Liposomes Sales by Type
6.3 APAC Liposomes Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Liposomes by Country
7.1.1 Europe Liposomes Sales by Country (2019-2024)
7.1.2 Europe Liposomes Revenue by Country (2019-2024)
7.2 Europe Liposomes Sales by Type
7.3 Europe Liposomes Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Liposomes by Country
8.1.1 Middle East & Africa Liposomes Sales by Country (2019-2024)
8.1.2 Middle East & Africa Liposomes Revenue by Country (2019-2024)
8.2 Middle East & Africa Liposomes Sales by Type
8.3 Middle East & Africa Liposomes Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Liposomes
10.3 Manufacturing Process Analysis of Liposomes
10.4 Industry Chain Structure of Liposomes
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Liposomes Distributors
11.3 Liposomes Customer
12 World Forecast Review for Liposomes by Geographic Region
12.1 Global Liposomes Market Size Forecast by Region
12.1.1 Global Liposomes Forecast by Region (2025-2030)
12.1.2 Global Liposomes Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Liposomes Forecast by Type
12.7 Global Liposomes Forecast by Application
13 Key Players Analysis
13.1 Johnson & Johnson
13.1.1 Johnson & Johnson Company Information
13.1.2 Johnson & Johnson Liposomes Product Portfolios and Specifications
13.1.3 Johnson & Johnson Liposomes Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Johnson & Johnson Main Business Overview
13.1.5 Johnson & Johnson Latest Developments
13.2 Gilead Sciences
13.2.1 Gilead Sciences Company Information
13.2.2 Gilead Sciences Liposomes Product Portfolios and Specifications
13.2.3 Gilead Sciences Liposomes Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Gilead Sciences Main Business Overview
13.2.5 Gilead Sciences Latest Developments
13.3 Pacira
13.3.1 Pacira Company Information
13.3.2 Pacira Liposomes Product Portfolios and Specifications
13.3.3 Pacira Liposomes Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Pacira Main Business Overview
13.3.5 Pacira Latest Developments
13.4 Sun Pharmaceutical
13.4.1 Sun Pharmaceutical Company Information
13.4.2 Sun Pharmaceutical Liposomes Product Portfolios and Specifications
13.4.3 Sun Pharmaceutical Liposomes Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Sun Pharmaceutical Main Business Overview
13.4.5 Sun Pharmaceutical Latest Developments
13.5 Luye Pharma
13.5.1 Luye Pharma Company Information
13.5.2 Luye Pharma Liposomes Product Portfolios and Specifications
13.5.3 Luye Pharma Liposomes Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Luye Pharma Main Business Overview
13.5.5 Luye Pharma Latest Developments
13.6 Sigma-Tau Group
13.6.1 Sigma-Tau Group Company Information
13.6.2 Sigma-Tau Group Liposomes Product Portfolios and Specifications
13.6.3 Sigma-Tau Group Liposomes Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Sigma-Tau Group Main Business Overview
13.6.5 Sigma-Tau Group Latest Developments
13.7 Fudan-Zhangjiang
13.7.1 Fudan-Zhangjiang Company Information
13.7.2 Fudan-Zhangjiang Liposomes Product Portfolios and Specifications
13.7.3 Fudan-Zhangjiang Liposomes Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Fudan-Zhangjiang Main Business Overview
13.7.5 Fudan-Zhangjiang Latest Developments
13.8 Teva Pharmaceutical
13.8.1 Teva Pharmaceutical Company Information
13.8.2 Teva Pharmaceutical Liposomes Product Portfolios and Specifications
13.8.3 Teva Pharmaceutical Liposomes Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Teva Pharmaceutical Main Business Overview
13.8.5 Teva Pharmaceutical Latest Developments
13.9 CSPC
13.9.1 CSPC Company Information
13.9.2 CSPC Liposomes Product Portfolios and Specifications
13.9.3 CSPC Liposomes Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 CSPC Main Business Overview
13.9.5 CSPC Latest Developments
13.10 Novartis
13.10.1 Novartis Company Information
13.10.2 Novartis Liposomes Product Portfolios and Specifications
13.10.3 Novartis Liposomes Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Novartis Main Business Overview
13.10.5 Novartis Latest Developments
13.11 Kingond Pharm
13.11.1 Kingond Pharm Company Information
13.11.2 Kingond Pharm Liposomes Product Portfolios and Specifications
13.11.3 Kingond Pharm Liposomes Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Kingond Pharm Main Business Overview
13.11.5 Kingond Pharm Latest Developments
13.12 Spectrum Pharmaceuticals
13.12.1 Spectrum Pharmaceuticals Company Information
13.12.2 Spectrum Pharmaceuticals Liposomes Product Portfolios and Specifications
13.12.3 Spectrum Pharmaceuticals Liposomes Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Spectrum Pharmaceuticals Main Business Overview
13.12.5 Spectrum Pharmaceuticals Latest Developments
13.13 Shanghai New Asia
13.13.1 Shanghai New Asia Company Information
13.13.2 Shanghai New Asia Liposomes Product Portfolios and Specifications
13.13.3 Shanghai New Asia Liposomes Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Shanghai New Asia Main Business Overview
13.13.5 Shanghai New Asia Latest Developments
14 Research Findings and Conclusion